Skip to content

    Chambal Fert.

    CHAMBLFERTGood
    Chemicals·6 Nov 2025
    Management Summary

    Chambal Fertilisers delivered a strong quarter characterized by robust revenue growth driven by a strategic shift back to higher P&K trading volumes and continued momentum in the high-margin Crop Protection segment. While Urea production faced minor operational headwinds from unscheduled maintenance, the company is successfully diversifying its portfolio with the upcoming TAN plant and biological offerings. Management remains optimistic about meeting FY26 volume targets despite rising global DAP prices and a complex subsidy environment.

    Highlights

    8
    • Standalone Revenue for Q2 FY26 stood at ₹6,413 crore, a significant 47.6% YoY increase from ₹4,346 crore.

    • Profit After Tax (PAT) grew by 20% YoY to ₹602 crore compared to ₹500 crore in the previous year.

    • Crop Protection and Speciality Nutrient (CPC) revenues increased 29% YoY to ₹374 crore with a 37% growth in contribution.

    • P&K fertiliser volumes are targeted to reach 1.1 million tons for FY26, nearly doubling from 5.5 lakh tons last year.

    • Technical Ammonium Nitrate (TAN) plant is on track for January 2026 operations with ₹1,052 crore spent till Sept '25.

    • Subsidy receipts for H1 FY26 were timely at ₹6,347 crore, though DAP subsidy remains high at ₹50,000-52,000 per ton.

    • Biological business achieved 80% revenue growth in H1 FY26, reaching ₹73 crore.

    • Urea production was slightly lower at 8.81 lakh metric tons due to an unscheduled stoppage at the Gadepan-III plant.

    Concerns

    1
    • Raw Material Price Volatility

    What Changed2

    vs Q3 FY26

    Guidance items7 → 4 (-3)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹6,413 Cr+47.6%YoY
    2. 02EBITDA₹882 Cr+5.8%YoY
    3. 03PAT₹602 Cr+20%YoY
    4. 04Urea Sales Volume9.34 lakh MT-3.2%YoY

    Segment breakdown

    Crop Protection and Speciality Nutrients
    ₹374 Cr Revenue₹114 Cr Contribution29.0% Revenue Growth
    Biologicals
    ₹73 Cr H1 Revenue80% H1 Revenue Growth
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Capacity
    TAN Plant Operational Commencement
    January 2026
    High
    Capacity
    IMACID Phosphoric Acid Capacity
    7 lakh metric tons
    Medium
    Volume
    P&K Fertiliser Annual Tonnage
    1.1 million tons
    High
    Other
    Digital Farmer Connect Subscribers
    3 to 5 lakh
    Medium

    Risks & concerns

    4
    RiskSeverity

    Raw Material Price Volatility

    Global DAP prices rose from $650 to $850, limiting pass-through ability and threatening P&K margins.Management acknowledged

    high

    Operational Stoppages

    Unscheduled stoppages at Gadepan-II (syngas compressor) and Gadepan-III (scrapper arm) led to a ~60,000-70,000 ton urea production shortfall in H1.Both acknowledged

    medium

    Subsidy Receivable Accumulation

    High DAP subsidy (₹50k-52k/ton) leads to working capital buildup; receivables increased by ₹2,100 crore this quarter.Analyst acknowledged

    medium

    GST Litigation

    Management views the GST notice on subsidy in Bihar as 'frivolous' and expects it to be overturned in court.Analyst downplayed

    low

    Q&A highlights

    3

    “if you see the current numbers and the cost of ammonia that we have, it's a healthy four-digit, five-digit margin in this business.”

    Reveals the strong unit economics of the upcoming TAN project due to captive ammonia advantage.

    asked by Keshav Garg, Counter Cyclical Investments

    2 min read5 chapters

    Detailed Narrative

    01

    P&K Segment Drives Revenue Surge

    The company saw a massive 47.6% jump in Q2 revenue, primarily driven by a strategic increase in P&K fertiliser trading. Management is targeting 1.1 million tons of P&K sales for FY26, a 100% increase from the 5.5 lakh tons achieved in the previous year. This growth is supported by an enabling subsidy framework, although rising global DAP prices from $650 to $850 per ton are expected to compress margins in the second half of the year.

    02

    TAN Project Nears Completion

    The Technical Ammonium Nitrate (TAN) plant is progressing according to schedule with ₹1,052 crore already invested. Trial runs for nitric acid are slated for December 2025, with full plant operations expected in January 2026. Management anticipates the product will hit the market by mid-February 2026 and expects a quick break-even due to a domestic supply shortage and the strategic advantage of captive ammonia feed.

    03

    High-Margin Crop Protection Momentum

    The Crop Protection and Speciality Nutrient business continues to be a star performer, with Q2 revenues growing 29% YoY to ₹374 crore. More impressively, the segment's contribution grew by 37%, maintaining high operating margins of approximately 30%. This performance is attributed to a successful placement strategy and the introduction of 22 new products in the first half of the year, which now contribute roughly 30% to segment volumes.

    04

    Operational Hurdles in Urea Manufacturing

    Urea production in Q2 was 8.81 lakh metric tons, down from 9.09 lakh metric tons last year, due to an unscheduled stoppage at the Gadepan-III plant caused by a broken scrapper arm. Combined with earlier syngas compressor issues at Gadepan-II, the total production shortfall for H1 stands at approximately 60,000-70,000 tons. Management expects to recover some of this volume through Gadepan-I and III, though Gadepan-II faces a planned turnaround in February 2026.

    05

    Subsidy and Working Capital Dynamics

    Subsidy receipts remained timely at ₹6,347 crore for the half-year. However, the high quantum of subsidy on DAP (over ₹50,000 per ton) has led to a temporary accumulation of receivables, which increased by ₹2,100 crore. Management expects these to liquidate as stocks move through the Point of Sale (POS) system by the end of December, normalizing the cash-to-cash cycle by Q4.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.